The ACR recently partnered with the American Medical Association (AMA) and a coalition of 16 other organizations representing physicians, medical groups, hospitals, pharmacists and patients to dramatically reshape prior-authorization protocols. The coalition is urging an industry-wide reassessment of these protocols to align with a newly created set of 21 principles, called the Prior Authorization and…
Articles by Cindy Devone-Pacheco
Psoriatic Arthritis Linked to Increased Heart Disease Risk
(Reuters Health)—Arthritis that accompanies the skin condition psoriasis may also come with a higher risk of heart problems, according to a Hong Kong study. In particular, patients with psoriatic arthritis may have a three- to four-fold higher prevalence of coronary atherosclerosis. Clinicians need to identify patients with high cardiovascular (CV) risk so they can provide…
Pfizer Announces Medicare Reimbursement for Inflectra (infliximab-dyyb), the First Biosimilar Monoclonal Antibody Available in the United States
On Jan. 6, Pfizer Inc. announced that the Centers for Medicare and Medicaid Services (CMS) has included payment information for INFLECTRA (infliximab-dyyb), a biosimilar to REMICADE (infliximab), in its January Average Selling Price (ASP) pricing file. This pricing took effect as of January 1, 2017. Additional claims processing information is listed in the MLN Matters…
Rituximab Promising for Dermatitis Herpetiformis
NEW YORK—Rituximab may be an effective treatment for recalcitrant dermatitis herpetiformis (DH), according to a recent case study. “DH is an autoimmune blistering disease which is commonly associated with celiac disease and can present with debilitating pruritic blisters on extensor surfaces,” explained Dr. Ron Feldman of Emory University School of Medicine. “The most common treatments…
Statin Use Tied to Attenuation of Tocilizumab-Mediated Lipid Increases
NEW YORK (Reuters Health)—Statin treatment is associated with an attenuation of the increases in serum lipids experienced by rheumatoid arthritis patients on tocilizumab, according to a post-hoc analysis of clinical trials. Treatment with the interleukin-6 receptor-alpha inhibitor tocilizumab is known to raise total cholesterol, LDL-cholesterol, HDL-cholesterol, and triglyceride levels. To explore the possible effect of…
Location & Ethnicity Affect Manifestations of Primary Sjogren’s Syndrome
NEW YORK (Reuters Health)—Geolocation and ethnicity exert a “strong influence” on the phenotype of primary Sjogren’s syndrome, researchers report. “The influence of ethnicity on the phenotypic expression of systemic autoimmune diseases has been suggested by various studies, especially in systemic lupus erythematosus, which has been reported as being more frequent and having less favorable outcomes…
Myocardial Inflammation Elevated in Active RA, Eases with DMARD Therapy
NEW YORK (Reuters Health)—Patients with active rheumatoid arthritis (RA) and no known heart disease may have subclinical myocardial inflammation, which improves with disease-modifying therapy, new research shows. “We know that patients with RA have higher risk of cardiovascular events, including heart failure and we really don’t know why. Maybe myocardial inflammation is one of the…
Anthem May Trim Obamacare Participation in 2018
(Reuters)—U.S. health insurer Anthem Inc on Wednesday raised the prospect of smaller participation in the individual Obamacare exchanges in 2018, saying it would have a market-by-market strategy that hinges on 2017 profitability. The company said that losses due to sicker-than-expected customers in its individual Obamacare plans were a bit less than foreseen in the third…
Brain Connectivity Predicts Placebo Response in Chronic Pain Patients
NEW YORK (Reuters Health)—Brain connectivity differences predict placebo responses in patients with chronic knee osteoarthritis, researchers report. Positive medical responses to placebo treatments are common, but the underlying central nervous system mechanisms remain unclear. Dr. Marwan N. Baliki and colleagues from the Feinberg School of Medicine at Northwestern University in Chicago used resting-state functional MRI…
Denosumab Linked to Rebound-Associated Fractures in Nine Patients
NEW YORK (Reuters Health)—Patients can develop rebound-associated vertebral fractures after stopping denosumab, a new report of nine cases shows. All of the patients were considered to be at low risk of fracture, and the fractures occurred within nine to 16 months of their last injection, Dr. Olivier Lamy and colleagues from Lausanne University Hospital in Switzerland…